Wellgistics Health (NASDAQ:WGRX) and TheracosBio Partner to Expand Nationwide, PBM-Free Access to Brenzavvy(R), an FDA-Approved Diabetes Therapy, Through 6,500+ Pharmacies
Wellgistics Health (NASDAQ:WGRX) has announced a strategic partnership with TheracosBio to expand nationwide access to Brenzavvy®, an FDA-approved diabetes therapy, through over 6,500 pharmacies. The collaboration leverages Wellgistics' "maker-to-taker" platform to bypass intermediaries, making the medication more affordable and accessible.
The initiative will integrate Brenzavvy into Wellgistics' AI-powered Tech & Hub platform in Q4 2025, enabling immediate patient onboarding through affiliated pharmacies and direct-to-patient channels. The partnership aims to address the needs of over 37 million Americans affected by Type 2 diabetes, where current out-of-pocket costs for SGLT-2 inhibitors can exceed $500 per month.
Wellgistics Health (NASDAQ:WGRX) ha annunciato una partnership strategica con TheracosBio per espandere l'accesso nazionale a Brenzavvy®, terapia diabetica approvata dall'FDA, attraverso oltre 6.500 farmacie. La collaborazione sfrutta la piattaforma "maker-to-taker" di Wellgistics per bypassare gli intermediari, rendendo il medicinale più conveniente e accessibile.
L'iniziativa integrerà Brenzavvy nella piattaforma Tech & Hub alimentata dall'IA di Wellgistics nel Q4 2025, consentendo l'immediata onboarding dei pazienti tramite farmacie affiliate e canali diretti al paziente. La partnership mira a rispondere alle esigenze di oltre 37 milioni di americani affetti da diabete di tipo 2, dove i costi out-of-pocket attuali per gli inibitori SGLT-2 possono superare $500 al mese.
Wellgistics Health (NASDAQ:WGRX) ha anunciado una asociación estratégica con TheracosBio para expandir el acceso nacional a Brenzavvy®, terapia para la diabetes aprobada por la FDA, a través de más de 6.500 farmacias. La colaboración aprovecha la plataforma "maker-to-taker" de Wellgistics para eliminar intermediarios, haciendo que el medicamento sea más asequible y accesible.
La iniciativa integrará Brenzavvy en la plataforma Tech & Hub impulsada por IA de Wellgistics en el Q4 2025, permitiendo la incorporación inmediata de pacientes a través de las farmacias afiliadas y de los canales directos al paciente. La asociación tiene como objetivo atender las necesidades de más de 37 millones de estadounidenses afectados por la diabetes tipo 2, donde los costos de bolsillo actuales para los inhibidores SGLT-2 pueden superar $500 al mes.
Wellgistics Health (NASDAQ:WGRX)는 FDA 승인을 받은 당뇨병 치료제 Brenzavvy®의 전국적 접근성을 6,500개 이상 약국을 통해 확대하기 위해 TheracosBio와 전략적 파트너십을 발표했습니다. 이 협력은 Wellgistics의 "maker-to-taker" 플랫폼을 활용하여 중개인을 우회하고 약물을 더 저렴하고 접근하기 쉽게 만듭니다.
이 이니셔티브는 Q4 2025에 Brenzavvy를 Wellgistics의 AI 기반 Tech & Hub 플랫폼에 통합하여 제휴 약국 및 환자 직송 채널을 통해 즉시 환자 온보딩을 가능하게 할 것입니다. 파트너십의 목표는 제2형 당뇨병에 영향을 받는 3700만 명 이상의 미국인들의 필요를 해결하는 것이며, 현재 SGLT-2 억제제의 자비 비용은 월 $500을 초과할 수 있습니다.
Wellgistics Health (NASDAQ:WGRX) a annoncé un partenariat stratégique avec TheracosBio pour étendre l'accès national à Brenzavvy®, une thérapie diabétique approuvée par la FDA, via plus de 6.500 pharmacies. La collaboration exploite la plateforme "maker-to-taker" de Wellgistics pour contourner les intermédiaires, rendant le médicament plus abordable et accessible.
L'initiative intégrera Brenzavvy dans la plateforme Tech & Hub alimentée par l'IA de Wellgistics au Q4 2025, permettant une intégration immédiate des patients via les pharmacies affiliées et les canaux Direct-to-Patient. Le partenariat vise à répondre aux besoins de plus de 37 millions d'Américains atteints de diabète de type 2, où les coûts de poche actuels pour les inhibiteurs SGLT-2 peuvent dépasser 500 dollars par mois.
Wellgistics Health (NASDAQ:WGRX) hat eine strategische Partnerschaft mit TheracosBio angekündigt, um den bundesweiten Zugang zu Brenzavvy®, einer von der FDA zugelassenen Diabetes-Therapie, über mehr als 6.500 Apotheken zu erweitern. Die Zusammenarbeit nutzt die "maker-to-taker"-Plattform von Wellgistics, um Zwischenhändler zu umgehen und das Medikament erschwinglicher und zugänglicher zu machen.
Die Initiative wird Brenzavvy in Wellgistics' KI-gestützte Tech & Hub-Plattform im Q4 2025 integrieren und so ein sofortiges Patienten-Onboarding über verbundene Apotheken und Direct-to-Patient-Kanäle ermöglichen. Die Partnerschaft zielt darauf ab, die Bedürfnisse von über 37 Millionen Amerikanern mit Typ-2-Diabetes zu adressieren, deren derzeitige Out-of-Pocket-Kosten für SGLT-2-Hemmer 500 USD pro Monat übersteigen können.
Wellgistics Health (NASDAQ:WGRX) أعلنت عن شراكة استراتيجية مع TheracosBio لتوسيع الوصول على مستوى البلاد إلى Brenzavvy®، علاج السكري المعتمد من FDA، عبر أكثر من 6,500 صيدلية. تستفيد الشراكة من منصة "maker-to-taker" الخاصة بـWellgistics لتخطي الوسطاء، مما يجعل الدواء أكثر توفيراً ومتاحة.
سيتم دمج Brenzavvy في منصة Tech & Hub المدعومة بالذكاء الاصطناعي من Wellgistics في الربع الرابع 2025، مما يتيح إدراج المرضى فوراً من خلال الصيدليات المتحالفة والقنوات المباشرة إلى المريض. تهدف الشراكة إلى تلبية احتياجات أكثر من 37 مليون أمريكي مصاب بمرض السكري من النوع 2، حيث قد تتجاوز التكاليف من الجيب للأ inhibitors SGLT-2 500 دولار شهرياً.
Wellgistics Health (NASDAQ:WGRX) 已宣布与 TheracosBio 建立战略伙伴关系，以通过超过 6,500 家药店扩大对 Brenzavvy® 的全国获取，该药物经 FDA 批准用于糖尿病治疗。此合作利用 Wellgistics 的 "maker-to-taker" 平台来绕过中间商，使药物更负担得起、更加易于获取。
该计划将在 Q4 2025 将 Brenzavvy 集成到 Wellgistics 的 AI 驱动 Tech & Hub 平台中，借助附属药店和直达患者渠道实现患者的即时入组。该伙伴关系旨在满足超過 3700万名美国人 的需求，患有 2 型糖尿病，而目前 SGLT-2 抑制剂的自付成本可能超过每月 $500。
- Partnership expands distribution to 6,500+ pharmacies nationwide
- Integration with AI-powered platform streamlines patient access and care coordination
- Elimination of middlemen reduces patient costs below typical insurance copayments
- Q4 2025 rollout positions company for near-term revenue growth
- Addresses large market opportunity with 37 million Americans affected by Type 2 diabetes
- Implementation and integration costs may impact short-term margins
- Success depends on pharmacy network adoption and participation
Insights
Wellgistics-TheracosBio partnership creates disruptive distribution model for diabetes medication, bypassing PBMs to potentially boost WGRX revenue.
This partnership represents a significant strategic development for Wellgistics Health that directly leverages its core "maker-to-taker" platform capabilities. The company is positioning itself as a disruptive force in the pharmaceutical value chain by enabling direct distribution of Brenzavvy (bexagliflozin) - an SGLT-2 inhibitor for type 2 diabetes - through its network of 6,500+ pharmacies while bypassing traditional pharmacy benefit managers (PBMs).
The market opportunity is substantial, with over 37 million Americans affected by type 2 diabetes and an estimated $327 billion in annual costs. More telling is that only one in eight eligible adults currently receives an SGLT-2 inhibitor, largely due to affordability barriers where out-of-pocket costs can exceed
What makes this deal particularly noteworthy is Wellgistics' application of technology to transform distribution economics. Their AI-driven hub platform will handle eligibility verification, claims processing, and adherence tracking - functions traditionally managed by PBMs at significant markups. By eliminating these intermediaries, Wellgistics aims to deliver the medication at costs potentially lower than typical insurance copayments.
The Q4 2025 implementation timeline signals a clear path to near-term revenue contribution, though specific financial projections are not provided. The model creates a multi-stakeholder win: patients gain affordable access to vital medications, pharmacies receive fair compensation, manufacturers secure a direct channel to patients, and Wellgistics positions itself to capture value previously absorbed by intermediaries in the supply chain.
TAMPA, FL / ACCESS Newswire / September 30, 2025 / Wellgistics Health, Inc. ("Wellgistics Health" or the "Company") (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced a strategic collaboration with TheracosBio, the manufacturer of Brenzavvy® (bexagliflozin), to make diabetes medications more affordable and accessible across the U.S. healthcare system.
The joint effort leverages Wellgistics Health's "maker-to-taker" platform - a direct pipeline that connects manufacturers to pharmacies and patients while bypassing costly intermediaries. With over 6,500 independent and chain pharmacies in its national network, Wellgistics Health will expand access to Brenzavvy through both traditional retail and direct-to-patient delivery models.
Key Benefits of the Collaboration
Expanded Access - Brenzavvy will be made available through the Wellgistics Health network of 6,500+ independent pharmacies, as well as participating chain pharmacies, reaching patients nationwide.
Affordability - By eliminating middlemen, this initiative is expected to lower costs to levels often below typical insurance copayments, easing patient cost burdens and increasing adherence.
Pharmacist Empowerment - Participating pharmacies will provide patient counseling, adherence support, and care coordination.
AI & Technology Integration - The Wellgistics Tech & Hub platform, powered by AI-driven modules, will streamline eligibility checks, claims adjudication, adherence tracking, and reporting.
Addressing an Urgent Need
Type 2 diabetes affects over 37 million Americans and costs the U.S. an estimated
Brenzavvy, a once-daily oral treatment, offers a cost-effective option within the SGLT-2 inhibitor class, designed to improve glycemic control in adults when used in conjunction with diet and exercise.
Executive Commentary
"Millions of Americans with type 2 diabetes still face affordability and access barriers at the pharmacy counter," said Brian Connelly, CEO of TheracosBio. "Through Wellgistics Health's streamlined approach, we are expanding access to Brenzavvy, helping patients afford their medications while empowering pharmacists to deliver meaningful care."
"Direct-to-patient affordability and access programs are a cornerstone of Wellgistics Health's mission," said Brian Norton, CEO of Wellgistics Health. "We are pioneering innovative models designed to not only expand patient access but also bring new levels of transparency and affordability to the healthcare system. By leveraging our technology-enabled platform and our national network of independent and chain pharmacies, we are striving to ensure powerful therapies like Brenzavvy are delivered efficiently, responsibly, and at a cost that patients can sustain."
Everyone Wins
Patients pay less and gain greater access to a vital class of diabetes medications.
Pharmacies receive fair compensation and tools to enhance patient care.
Employers and Health Plans see expedited and transparent savings without waiting for rebate reconciliations.
Manufacturers gain a direct, efficient channel to reach patients and expand therapy adoption.
Execution Roadmap
Brenzavvy will be integrated into the Wellgistics Tech & Hub and Distribution platform beginning in Q4 2025, enabling immediate patient onboarding through affiliated pharmacies and direct-to-patient channels.
Q4 2025 rollout positions WGRX for near-term revenue impact.
This collaboration underscores Wellgistics Health's aim to be a disruptive force in pharmaceutical distribution, redefining how therapies move from manufacturer to patient with transparency, affordability, and scale.
About TheracosBio
TheracosBio is a biopharmaceutical company dedicated to developing and commercializing therapies that address unmet needs in chronic disease management. Its lead product, Brenzavvy, was developed to provide an effective, affordable SGLT-2 inhibitor option for adults with type 2 diabetes.
For full prescribing information, visit www.theracosbio.com.
About Wellgistics Health, Inc.
Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.
For more information, visit www.wellgisticshealth.com.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.
Media & Investor Contact
Media:
media@wellgisticshealth.com
Investor Relations:
IR@wellgisticshealth.com
Investor Relations Contact
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com
SOURCE: Wellgistics Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the partnership between Wellgistics Health (NASDAQ:WGRX) and TheracosBio?
How will the WGRX partnership affect diabetes medication costs?
When will Wellgistics Health (WGRX) implement the Brenzavvy distribution program?
How many pharmacies are in the Wellgistics Health (WGRX) network?
What technology is Wellgistics Health (WGRX) using for the Brenzavvy distribution?
